Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PER Pulse™ Recaps highlight key points presented in Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment and Management of Breast Cancer. The first PER Pulse™ Recap focuses on data from the phase III PALOMA-2 trial of first-line palbociclib for hormone receptor-positive, HER2-negative, advanced breast cancer. The second PER Pulse™ Recap focuses on results of the MA.17R trial of 5 years of extended letrozole therapy after 5 years of aromatase inhibitor therapy for early-stage breast cancer.
This activity is supported by an educational grant from Lilly.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
This activity is designed to update participants on the most clinically impactful data on breast cancer treatment, presented at the annual 2016 Chicago meeting, so they can assess and prepare to apply these findings to their clinical practices.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical and surgical oncologists who treat patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with breast cancer are also invited to participate.
Ruth O'Regan, MD
Chief, Division of Hematology/Oncology
Carbone Cancer Center
University of Wisconsin
Disclosure: Consultant: Genentech, Pfizer, AstraZeneca
Pamela Munster, MD
Professor of Medicine (Hematology/Oncology)
Program Leader, Developmental Therapeutics Program
Director, Early Phase Clinical Trials Unit
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA
Disclosure: Research Support: Merck, Novartis, BioMarin, Merrimack Pharmaceuticals, Calithera, Celgene; Consultant: Huya Bioscience International
The following individuals have no relevant financial relationships with commercial interests:
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY